We therefore decided to test, whether activation of PPARγ by rosiglitazone, a compound of this class that is in clinical use, might result in reduced nuclear accumulation of pSmad2 and suppression of atherosclerosis in mice lacking LRP1. The gene discussed is LRP1; the disease is atherosclerosis.